Table 5 –
Risk factors for progression among men with stable MRI (PRECISE score <4).
| Stable MRI (PRECISE score of <4) | Progression from GG1 to ≥ GG2 |
Progression from GG1 to ≥ GG3 |
||||
|---|---|---|---|---|---|---|
| Univariable |
Multivariable |
Univariable |
||||
| OR (95% CL) | p value | OR (95% CL) | p value | OR (95% CL) | p value | |
|
| ||||||
| Age (per decade) | 1.11 (0.705–1.748) | 0.651 | – | – | 1.664 (0.65–4.259) | 0.288 |
| PSA (log base 2) | 1.227 (0.915–1.645) | 0.172 | – | – | 1.811 (1.145–2.864) | 0.011 |
| PSAD (log base 2) | 1.676 (1.138–2.468) | 0.009 | 1.393 (0.894–2.172) | 0.143a | 1.951 (1.172–3.246) | 0.01 |
| ΔPSA (log base 2) | 2.174 (1.201–3.935) | 0.01 | 1.741 (0.904–3.354) | 0.097a | 1.961 (0.476–8.07) | 0.351 |
| ΔPSAD (log base 2) | 2.234 (1.117–4.467) | 0.023 | – | – | 1.409 (0.368–5.389) | 0.617 |
| Number of lesions | 1.32 (1.011–1.724) | 0.041 | – | – | 1.023 (0.583–1.795) | 0.936 |
| size of lesions (per mm) | 1.089 (1.024–1.159) | 0.007 | 1.07 (1.005–1.14) | 0.035 | 1.019 (0.904–1.148) | 0.76 |
| PI-RADS ≥4 vs <4 | 1.467 (0.677–3.178) | 0.331 | – | – | 0.94 (0.165–5.344) | 0.944 |
| NIH ≥ moderate vs < moderate | 1.555 (0.813–2.977) | 0.182 | – | – | 3.929 (0.812–19.004) | 0.089 |
CL = confidence limit; GG = Gleason grade group; MRI = magnetic resonance imaging; NIH = National Institutes of Health; OR=odds ratio; PI-RADS = Prostate Imaging Reporting and Data System; PRECISE = Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation; PSA=prostate-specific antigen; PSAD = prostate-specific antigen density.
a
Combined effect of PSAD and ΔPSA was significant (p = 0.024).